J.M. Dutton & Associates Announces Investment Opinion: GlycoGenesys Speculative Buy Rating In Initiating Coverage By Dutton & Associates
Business Wire - January 20, 2004 12:00
EL DORADO HILLS, Calif., Jan 20, 2004 (BUSINESS WIRE) -- J.M. Dutton & Associates initiates coverage of GlycoGenesys (Nasdaq:GLGS) with a Speculative Buy rating. The 19-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from Bloomberg, Zacks, First Call, Multex, and other leading financial portals.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging scientific discipline built around the interaction of carbohydrates and sugars with proteins, lipids, and other molecules. Glycobiologists, scientists who study carbohydrates and sugars, are discovering that glycosylation, the process by which carbohydrates and sugars form conjugates with biologically active molecules such as proteins, plays a major role in embryonic development, cell differentiation, inflammation and oncogenesis. GlycoGenesys is one of only a handful of companies with an established intellectual property base in glycomics, and a glyco-compound already in human clinical trials. The Company's lead compound, GCS-100, has already demonstrated a broad spectrum of activity as an anticancer agent, including several mechanistic properties similar to that of currently leading anti-cancer therapeutics. GCS-100 may be one of a new breed of anti-cancer agents that act through multiple independent pathways. The potential to mediate cancer cell metastasis and circumvent cancer cell immortality gives GCS-100 an exciting potential therapeutic profile. We therefore rate the shares a Speculative Buy.
About Dutton & Associates
Dutton & Associates is one of the largest independent investment research firms in the U.S. Its 24 senior analysts are primarily CFAs, and have expertise in many industries. Dutton & Associates provides continuing analyst coverage of over 60 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $28,000 prepaid before commencement of our research activities. We received $25,000 from the Company for coverage for the year, and do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
SOURCE: J.M. Dutton & Associates |
